70.11 0.00 (0.00%)
After hours: 4:44PM EST
|Bid||69.00 x 1000|
|Ask||74.31 x 100|
|Day's Range||69.82 - 70.97|
|52 Week Range||37.35 - 75.98|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
On November 1, 2017, Neurocrine Biosciences, Inc. (NBIX) announced financial results for the third quarter of 2017 and provided a business update. The company reported $45.8 million in revenues from the sale of INGREZZA® for the treatment of tardive dyskinesia (TD), which was way ahead of even the most optimistic expectations. On October 5, 2017, the company announced that the FDA approved the 80 mg capsule of INGREZZA®.
The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX )'s third-quarter results . Given the buoyancy surrounding Ingrezza, ...
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
Neurocrine Biosciences, Juno Therapeutics and Exelixis topped expectations, though Clovis Oncology lagged.
On a per-share basis, the San Diego-based company said it had a loss of 13 cents. The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research ...
In the first half of 2017, Neurocine Biosciences (NBIX) generated revenues of $6.3 billion and reported expenses on the cost of product sales of $61.0 million.
Neurocrine Biosciences Inc. shares rose 3% in premarket trade Thursday after the company said the Food and Drug Administration has approved a higher, 80 mg dose of its tardive dyskinesia drug. The 80 mg ...
Neurocrine Biosciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.